The Board of Directors of Le Travenues Technology Limited approved a significant further investment of €15.3 Million (equivalent to ₹153 Crore) into its wholly owned Singapore subsidiary, IXIGO PTE. LTD., for strategic European expansion. Additionally, the board approved the allotment of 112,220 fully paid-up equity shares following the exercise of options under various Employee Stock Option Schemes (ESOS 2016, 2021, and 2024). This allotment increased the paid-up share capital to ₹438,183,527.
Key Board Resolutions Approved on February 13, 2026
At the Board meeting held on Friday, February 13, 2026, Le Travenues Technology Limited (the Company) finalized two primary resolutions concerning capital allocation and employee incentives. The meeting commenced at 06:45 P.M. (IST) and concluded at 07:47 P.M. (IST).
Strategic Investment in IXIGO PTE. LTD.
The Board approved a further investment in IXIGO PTE. LTD., the Company’s wholly owned subsidiary incorporated in Singapore on December 18, 2025. This subsidiary is tasked with leading investment and strategic management initiatives, particularly focusing on the Group’s international expansion and strengthening business synergies, specifically targeting acquisitions in Europe.
The key details of this investment are:
- Consideration: Cash consideration equivalent to €15,300,000 (Fifteen Million Three Hundred Thousand Euros).
- Pricing: Approved at par value, i.e., €1 per share.
- Ownership: The Company will continue to hold 100% of the share capital of IXIGO PTE. LTD.
- Timeline: The completion of this investment is targeted on or before March 31, 2026.
Allotment of Equity Shares via ESOP Exercise
The second major item approved was the allotment of 112,220 fully paid-up equity shares resulting from the exercise of vested stock options by employees under ESOS 2016, ESOS 2021, and ESOS 2024.
This issuance had the following financial impact:
- Increase in Share Capital: Paid-up share capital increased from ₹438,071,307/- to ₹438,183,527/-.
- Money Realized: The Company realized ₹467,088.50/- from the exercise.
- Pricing Basis: The exercise price was determined based on the fair market value (closing price on the date prior to grant approval), though the final price could not be below the par value of ₹1 per share.
Status of Outstanding Options
Following the allotment, the number of remaining vested options as of February 13, 2026, across the schemes are:
| Scheme | No. of Vested Options Remaining |
|---|---|
| ESOS 2016 | 169,341 |
| ESOS 2021 | 2,086,381 |
| ESOS 2024 | 326,266 |
It was noted that the shares allotted will rank pari passu with the existing equity shares of the Company. The disclosure related to diluted earnings per share will be submitted later with the financial results.
Trading Window Closure Update
The announcement also clarified that the trading window for designated persons and their immediate relatives will reopen effective February 16, 2026, as they will no longer possess unpublished price-sensitive information.
Source: BSE
